VAL-083 updated results, page-5

In the Newly-Diagnosed Treatment Setting, Promising Median Progression-Free Survival of 10.0 months with VAL-083 Compared to Temozolomide (TMZ) Historical Data (5.3 months* and 6.9 months**, respectively)- Recurrent Patients Showing Promising Median Overall Survival of 8.5 Months on the Planned 30 mg/m2/day Phase 3 Initial Dose of VAL-083 Compared to Lomustine Historical Data (7.2 months***)
..........
Any life-extension is good. Still I'm not impressed enough to be worried. If I were a kid, I'd worry about needles. I could be distracted once or twice, but sooner or later, I'd catch on. 3 more months of terror, I'd say no.